BAM
ARLZ

Berkshire Asset Management’s Aralez Pharmaceuticals Inc. ARLZ Stock Holding History

Berkshire Asset Management’s Portfolio ARLZ Stock Details ARLZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-15,000
Closed -$21K – 221
2017
Q4 		$21K Buy
+15,000
New +$24.6K ﹤0.01% 205

Other funds holding ARLZ

PCM
PAR Capital Management Boston, Massachusetts $3.45B AUM 28.5% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return
DZ Bank
DZ Bank Frankfurt Am Main, Germany $113B AUM 36.92% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
BAS
Brown Advisory Securities Baltimore, Maryland $27.3M AUM 10.67% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
SM
Salzhauer Michael $292M AUM 30% 1-Year Est. Return

Berkshire Asset Management's ARLZ Position: Q1 2018 in Review

Berkshire Asset Management sold out of Aralez Pharmaceuticals Inc. (ARLZ) in Q1 2018, closing a stake of 15,000 shares — an estimated $21K sold.

Berkshire Asset Management first reported a position in ARLZ in Q4 2017 and held it in 1 quarter. The position peaked at $21K in Q4 2017. 56 funds tracked by Wall St. Rank hold ARLZ as of Q1 2018.

  • Berkshire Asset Management reported no remaining Aralez Pharmaceuticals Inc. position as of Q1 2018 after selling out during the quarter.
  • Berkshire Asset Management sold 15,000 Aralez Pharmaceuticals Inc. shares in Q1 2018, an estimated $21K.
  • Berkshire Asset Management first reported a position in Aralez Pharmaceuticals Inc. in Q4 2017 and held it in 1 quarter.
  • Berkshire Asset Management's Aralez Pharmaceuticals Inc. position peaked at $21K in Q4 2017.
  • 56 funds tracked by Wall St. Rank held Aralez Pharmaceuticals Inc. as of Q1 2018.

Based on Berkshire Asset Management's 13F filing for Q1 2018, filed 1 May 2018.